KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查

Nivolumab plus ipilimumab: A promising first-line therapy for hepatocellular carcinoma.

Bernardo Stefanini, Fabio Piscaglia

Med 6(8) 100783

PMID40782666
PMCID-
DOI10.1016/j.medj.2025.100783
发表日期2025-08-09
摘要

摘要

Recently published in The Lancet, CheckMate 9DW evaluated the efficacy and safety of dual immune checkpoint blockade nivolumab plus ipilimumab (Nivo/Ipi) compared to either sorafenib or lenvatinib in treatment-naive patients with unresectable hepatocellular carcinoma. This open-label, randomized phase 3 trial demonstrated that Nivo/Ipi provides an overall survival benefit versus lenvatinib or sorafenib.1.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。